Member Info for Abouttime

3.3 millions buy

40k coming in

Airtel Africa operates in telecommunications, offering mobile and internet services.

Airtel Africa purchased 398,773 shares in its buy-back program to optimize capital.

News tomorrow

Shield Therapeutics (STX), a commercial stage pharmaceutical company specialising in iron deficiency with or without anaemia (“ID/IDA”), announced that it has entered into an exclusive licence agreement for ACCRUFeR® with VITAL-NET, Inc. in Japan. VITAL-NET will undertake and be responsible for all costs, including clinical and regulatory, related to activities required to achieve marketing authorisation and commercialisation of ACCRUFeR® in Japan. Shield will receive an initial payment of circa $665,000

We feel now is a pretty good time to analyse Shield Therapeutics plc's (LON:STX) business as it appears the company may be on the cusp of a considerable accomplishment. Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. The UK£39m market-cap company announced a latest loss of US$27m on 31 December 2024 for its most recent financial year result. As path to profitability is the topic on Shield Therapeutics' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Consensus from 3 of the British Pharmaceuticals analysts is that Shield Therapeutics is on the verge of breakeven.

Good start

Hopefully 7p end of August breakeven news then 8p

Another 22k buy

We just need news, this will fly.

This is moving in the right direction, looking forward to news.

14 November

Flecting a positive outlook for the year. The Spring selling season has progressed as expected, and the company's net private sales rate is up compared to the previous year, although the cancellation rate is slightly higher. Taylor Wimpey is also seeing a strong order book, with a total value of GBP2.34 billion.

Taylor Wimpey plc (LON:TW - Get Free Report) insider Chris Carney acquired 133 shares of the business's stock in a transaction on Tuesday, July 8th. The shares were purchased at an average price of GBX 112 ($1.52) per share, for a total transaction of £148.96 ($202.50).

Taylor Wimpey plc (LON:TW - Get Free Report) insider Jennie Daly purchased 134 shares of the business's stock in a transaction dated Tuesday, July 8th. The stock was bought at an average cost of GBX 112 ($1.52) per share, with a total value of £150.08 ($203.97).

Buys today

211k buy

Https://share.google/K79sbOfHhbpBWEooH

I sold my holdings. Too much risk. Bought in on Sheild therapeutics STX .

This might go up more, but it could drop fast too. Good luck everyone.

I'm in on Taylor wimpey, shield therapeutics, sqz , mast at 27k 1.08 buy.